NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

In the DCVax-L trial, all patients were treated with SOC, and DCVax-L was added. The timing of the SOC treatment in the DCVax-L trial was the same as the timing of the SOC in all of the ECA trials. There is no randomization timing difference.

ATLnsider,
I agree.

I ask Linda Liau about that footnote:

Dear Professor Linda Liau,

Thanks for the enlightening presentation today at the University of Utah.
I have a question about the footnote on slide 21:

"Gilbert 2014 randomized study subjects at an earlier timepoint then the other studies, and all analyses will be conducted both including and excluding this study."

What kind of analyses do you mean?

Kind regards,

Reply this morning from Linda Liau:

Any analysis that would use this study as an external control comparator.

LL

New endpoints:

The primary objective of this study is to compare overall survival (OS) between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma. This endpoint will be assessed using 3 different analyses.

https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001977-13/DE